Figure 1From: Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of lifeDisease-free survival (DFS) of resected pancreatic cancer patients who received adjuvant chemotherapy with bi-weekly gemcitabine (GEM: Group A) versus 5FU-based (5FU: Group B). mo., months (Log-rank test P < 0.001).Back to article page